Send to

Choose Destination
Diabetes Metab Syndr Obes. 2015 Feb 4;8:89-96. doi: 10.2147/DMSO.S78877. eCollection 2015.

Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins.

Author information

Scientific Department, Velleja Research, Milan, Italy.
ASL TO1, Turin, Italy.
AIOR, Pontenure, Province of Piacenza, Italy.
University Hospital San Gerardo, Monza, Italy.



Statin intolerance is a medical condition often leading patients to nonadherence to the prescribed therapy or to a relevant reduction of the statin dosage. Both situations determine a totally or partially uncontrolled lipid profile, and these conditions unquestionably increase the risk of cardiovascular events.


We enrolled hypercholesterolemic, type 2 diabetic patients complaining of intolerance to statins. Some of them had reduced the statin dose 'until the disappearance of symptoms'; others had opted for treatment with ezetimibe; and yet others were not undergoing any treatment at all. All patients of the three groups were then given a fixed combination of berberine and silymarin (Berberol(®)), known from previous papers to be able to control both lipidic and glycemic profiles.


The tested product both as a single therapy and as add-on therapy to low-dose statin or to ezetimibe reduced triglycerides, low-density lipoprotein cholesterol, fasting blood glucose, and glycosylated hemoglobin in a significant manner without inducing toxicity conditions that might be somehow ascribed to a statin-intolerant condition.


Our study demonstrates that use of Berberol(®), administered as a single or add-on therapy in statin-intolerant subjects affected by diabetes and hypercholesterolemia is a safe and effective tool capable of improving the patients' lipidic and glycemic profiles.


Berberol®; berberine; cholesterol; ezetimibe; silymarin; type 2 diabetes

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center